Fodor, Andrei
Giannini, Laura
Torrisi, Miriam
Brombin, Chiara
Broggi, Sara
Losa, Andrea
Maga, Tommaso
Mellone, Renata
Martinenghi, Carlo
Tummineri, Roberta
Mangili, Paola
Deantoni, Chiara Lucrezia
Tudda, Alessia
Castriconi, Roberta
Rancoita, Paola Maria Vittoria
Di Serio, Mariaclelia Stefania
Gaboardi, Franco
Fiorino, Claudio
Del Vecchio, Antonella
Chiti, Arturo
De Cobelli, Francesco
Di Muzio, Nadia
Clinical trials referenced in this document:
Documents that mention this clinical trial
Comprehensive one-day management of prostate cancer patients: PRO-FAST single-fraction ablative, urethral-sparing, HDR-like, robotic SBRT
https://doi.org/10.1186/s13014-025-02713-9
Article History
Received: 21 May 2025
Accepted: 11 August 2025
First Online: 27 August 2025
Declarations
:
: All procedures performed in the present study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies using animals performed by any of the authors. This study has been approved by the Institutional Scientific Board of the IRCCS San Raffaele Scientific Institute (registration number 27/INT//2023). All participants will sign an Informed Consent.
: Not applicable.
: Miriam Torrisi and Roberta Tummineri received a speaker honorarium from Accuray Inc. independently from the current work. Laura Giannini received a research fellowship from AIRC: IG 25951-project “Toward clinical use of PET in selecting patients with pancreatic cancer for local treatment intensification”. Miriam Torrisi received a research grant from the Next Generation EU (PNRR-MCNT2-2023-12378239), with a project entitled “Radio-immunotherapy in solid tumors” (CUP Code: C43C24000320005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The remaining authors declare no conflicts of interest.